Evidence map›Paper›PMID 35159184›Full record

ArticleCells2022

The Fairy Chemical Imidazole-4-carboxamide Inhibits the Expression of Axl, PD-L1, and PD-L2 and Improves Response to Cisplatin in Melanoma.

Chisa Inoue, Taro Yasuma, Corina N D'Alessandro-Gabazza, Masaaki Toda, Valeria Fridman D'Alessandro, Ryo Inoue, Hajime Fujimoto, Hajime Kobori, Suphachai Tharavecharak, Atsuro Takeshita and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Bioactive Compounds from the Mushroom-Forming FungusAntibiotics (Basel, Switzerland) · 2023
    Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Chisa InoueDepartment of Diabetes, Metabolism and Endocrinology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.ORCID 0000-0002-7022-9156
Taro YasumaDepartment of Diabetes, Metabolism and Endocrinology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Corina N D'Alessandro-GabazzaDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Masaaki TodaDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Valeria Fridman D'AlessandroDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.ORCID 0000-0003-2164-5775
Ryo InoueDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Hajime FujimotoDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Hajime KoboriIwade-Research Institute of Mycology Co., Ltd., Tsu 514-0012, Japan.
Suphachai TharavecharakDepartment of Agriculture, Graduate School of Agriculture, University of Miyazaki, Miyazaki 889-2192, Japan.
Atsuro TakeshitaDepartment of Diabetes, Metabolism and Endocrinology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Kota NishihamaDepartment of Diabetes, Metabolism and Endocrinology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Yuko OkanoDepartment of Diabetes, Metabolism and Endocrinology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Jing WuResearch Institute of Green Science and Technology, Shizuoka University, Shizuoka 422-8529, Japan.ORCID 0000-0002-1139-7010
Tetsu KobayashiDepartment of Pulmonary and Critical Care Medicine, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Yutaka YanoDepartment of Diabetes, Metabolism and Endocrinology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.
Hirokazu KawagishiResearch Institute of Green Science and Technology, Shizuoka University, Shizuoka 422-8529, Japan.
Esteban C GabazzaDepartment of Immunology, Mie University Faculty and Graduate School of Medicine, Tsu 514-8507, Japan.ORCID 0000-0001-5748-1499
Mie University · JPShizuoka University · JPUniversity of Miyazaki · JP

Funding

Takeda Science Foundation 2019
6 · The paper itself

Abstract

The leading cause of death worldwide is cancer. Many reports have proved the beneficial effect of mushrooms in cancer. However, the precise mechanism is not completely clear. In the present study, we focused on the medicinal properties of biomolecules released by fairy ring-forming mushrooms. Fairy chemicals generally stimulate or inhibit the growth of surrounding vegetation. In the present study, we evaluated whether fairy chemicals (2-azahypoxanthine, 2-aza-8-oxohypoxanthine, and imidazole-4-carboxamide) exert anticancer activity by decreasing the expression of Axl and immune checkpoint molecules in melanoma cells. We used B16F10 melanoma cell lines and a melanoma xenograft model in the experiments. Treatment of melanoma xenograft with cisplatin combined with imidazole-4-carboxamide significantly decreased the tumor volume compared to untreated mice or mice treated cisplatin alone. In addition, mice treated with cisplatin and imidazole-4-carboxamide showed increased peritumoral infiltration of T cells compared to mice treated with cisplatin alone. In vitro studies showed that all fairy chemicals, including imidazole-4-carboxamide, inhibit the expression of immune checkpoint molecules and Axl compared to controls. Imidazole-4-carboxamide also significantly blocks the cisplatin-induced upregulation of PD-L1. These observations point to the fairy chemical imidazole-4-carboxamide as a promising coadjuvant therapy with cisplatin in patients with cancer.

Indexed as

CisplatinMelanomaAminoimidazole CarboxamideAnimalsB7-H1 AntigenHumansImmune Checkpoint ProteinsMiceAminoimidazole CarboxamideB7-H1 AntigenCisplatinimidazole-4-carboxamideImmune Checkpoint ProteinsAxlcancerdrug resistancefairy chemicalsimmune checkpoint moleculesmushroom

Identifiers

PMID35159184
PMCPMC8834508
OpenAlexW4207004052

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.